DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

B. Riley FBR Maintains Buy on Galmed Pharmaceuticals, Lowers Price Target to $11

B. Riley FBR analyst Mayank Mamtani maintains Galmed Pharmaceuticals (NASDAQ:GLMD) with a Buy and lowers the price target from $28 to $11.

Benzinga · 03/13/2020 11:37

B. Riley FBR analyst Mayank Mamtani maintains Galmed Pharmaceuticals (NASDAQ:GLMD) with a Buy and lowers the price target from $28 to $11.